登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
SKB500 Combinations in Patients With Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07296809,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed Extensive-stage small cell lung cancer (ES-SCLC):
入选标准第 2 条
Cohort 1: participant has received or not received prior systemic treatment, with no more than 1 prior systemic therapy in the extensive stage.
入选标准第 3 条
Cohort 2\~3: participant has received no prior systemic treatment.
入选标准第 4 条
Has recovered to grade ≤ 1 of prior anti-cancer treatment toxicities.
入选标准第 10 条
Effective contraceptive methods should be used during the study and for 6 months after the end of treatment.
入选标准第 11 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 7 条
Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
入选标准第 6 条
Pregnant or lactating women.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07296809,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female participants between 18 and 75 years old. Histologically or cytologically confirmed Extensive-stage small cell lung cancer (ES-SCLC): Cohort 1: participant has received or not received prior systemic treatment, with no more than 1 prior systemic therapy in the extensive stage. Cohort 2\~3: participant has received no prior systemic treatment. Agree to provide fresh or archival tumor tissue for biomarker analysis. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy >= 12 weeks. Has adequate organ and bone marrow functions. Has recovered to grade ≤ 1 of prior anti-cancer treatment toxicities. Effective contraceptive methods should be used during the study and for 6 months after the end of treatment. Voluntarily join this study, sign the informed consent form, and can comply with the protocol-specified visits and procedures.排除标准:Exclusion Criteria:
The pathology suggests the presence of both non-small cell carcinoma and small cell carcinoma components. Has previously received medications with the same target or the same toxins. Presence of spinal cord compression or clinically active central nervous system metastases. Presence of clinical symptoms caused by tumor invasion or compression of important organs and blood vessels. Severe infection within 4 weeks or active infection requiring systemic anti-infective treatment within 2 weeks prior to the first dose. With peripheral neuropathy of grade ≥ 2. History of any serious, life threatening, or permanently discontinuing adverse events mediated by immunotherapy, including infusion reactions. Presence of uncontrolled concurrent diseases, including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, Severe active peptic ulcer, gastrointestinal bleeding, gastrointestinal perforation, intestinal obstruction, etc. Serious or uncontrolled heart disease or clinical symptoms requiring treatment. History of interstitial lung disease (ILD) /noninfectious pneumonitis that require steroid treatment, or currently has ILD/noninfectious pneumonitis. Clinical severe lung damage caused by concurrent lung disease. Uncontrolled hypertension, diabetes, or repeated drainage of pleural effusion/pericardial effusion/ abdominal effusion. Pregnant or lactating women. Rapid disease deterioration in the screening process.
引自 ClinicalTrials.gov, NCT07296809, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07296809,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。